Skip to content

Aqilion CEO Sarah Fredriksson on August 18, 2023:


Aqilion runs four innovative R&D programs. All with focus on developing novel innovative treatments for chronic inflammatory diseases for which few or no treatments are available and where there is currently a clear patient need.


Interim Reports are distributed to shareholders only.

What we do

Research is at the heart of what we do. The Aqilion team and network has extensive expertise and experience in pursuing research to develop innovative medicines that can make a difference in the treatment of diseases in which the body’s inflammatory processes play a major role.